Monitor pipeline advancement, particularly phase progression of zumilokibart; assess whether capital raise supports extended runway without near-term dilution risk.
APGE drugs
APGE drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 27 $77.82entry
- T+1 · 8mo ago +1.16%α +1.51% · $78.72
- T+5 · 8mo ago +7.95%α +4.09% · $84.01
- T+20 · 7mo ago +11.12%α −1.63% · $86.47
- T+60 · 5mo ago +70.66%α +54.59% · $132.81
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Apogee Therapeutics completed a public offering of 5,750,000 shares at $70.00 per share, raising approximately $403 million in gross proceeds. The capital will support development of its clinical-stage biologics pipeline in inflammatory and immunology indications.
Key Financial Metrics
Key Facts
- Apogee Therapeutics closed an underwritten public offering of 5,750,000 shares of common stock
- Offering price was $70.00 per share, with full exercise of underwriters' option for 750,000 additional shares
- Aggregate gross proceeds were approximately $403 million before expenses
- Proceeds will be used to advance clinical development of Apogee's biologics pipeline, including zumilokibart (APG777) for atopic dermatitis, asthma, and EoE
- Jefferies, TD Cowen, Stifel, and Guggenheim Securities acted as joint book-running managers
Financial Impact
$403 million in gross proceeds, dilutive to existing shareholders by approximately 5.75M shares
Risk Factors
- Dilution to existing shareholders from issuance of new shares
- Execution risk in advancing clinical programs despite funding
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3263384 |
Track record
31 reports on APGE
9 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +73.31% at T+60 after the May 27, 2026 report. 12 of 13 went positive at some point.
Filters
- Sep 14, 20269w ago 15-12G Neutral 4/10 No price data
- Sep 3, 202610w ago 25-NSE Bullish 8/10 Entry $135.06 No price data
- Sep 3, 202610w ago 8-K Bullish 8/10 Entry $135.06 No price data
- Aug 11, 202613w ago 8-K Bullish 7/10 Entry $134.55 No price data
- Aug 10, 202614w ago 8-K Bullish 8/10 No price data
- Aug 10, 202614w ago Press Release Bullish 8/10 Entry $134.65 No price data
- Aug 6, 202614w ago Institutional Cluster Mixed 5/10 Entry $134.49 to $135.07 ▲ +0.43% −0.17% vs SPY
- Aug 3, 202615w ago DEFA14A Bullish 5/10 Entry $134.19 to $135.08 ▲ +0.66% +1.90% vs SPY
- Jul 10, 202618w ago Insider Cluster Neutral 2/10 Entry $133.82 to $134.65 ▲ +0.62% −2.56% vs SPY
- Jun 26, 202620w ago DEFA14A Bullish 6/10 Entry $132.61 to $134.28 ▲ +1.26% +1.54% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers